Health Corporation of the Ziv Medical Center (R.A.)

Safed 1311001

0 studies enrolling now · 5 studies all time

What they study most

Acute Non-cardioembolic Ischemic Stroke, Cancer, Chronic Heart Failure With Preserved Ejection Fraction, Chronic Kidney Disease, Heart Failure, High-risk Transient Ischemic Attack, Prevention of Ischemic Stroke, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes — Completed
• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Running, not enrolling
• A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke — Completed
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
• Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF — Completed